J. Gossmann et al., ANEMIA IN RENAL-TRANSPLANT RECIPIENTS CAUSED BY CONCOMITANT THERAPY WITH AZATHIOPRINE AND ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS, Transplantation, 56(3), 1993, pp. 585-589
Immunosuppression of recipients of renal transplants with azathioprine
has been associated with two major side effects: hepatotoxicity and m
yelotoxicity, mainly in the form of leukopenia. Reports of isolated an
emia in these patients have been rare. We now observed the development
of severe anemia in 9 out of 11 renal transplant recipients whose imm
unosuppressive regimen was converted from cyclosporine plus prednisone
to azathioprine plus prednisone. A significant (P=0.001) drop in hema
tocrit (from 34+/-4% to 27+/-3%, mean +/- SD) and hemoglobin (from 11.
6+/-1.3 g/dl to 9.5+/-1.0 g/dl) was found. Since a common variable of
all these patients was their use of an angiotensin-converting enzyme (
ACE) inhibitor as antihypertensive medication, we speculated that the
combination of azathioprine and ACE blocker might be the reason for th
e anemia. We then compared 2 groups of 10 patients each who had been o
n azathioprine as their regular immunosuppressive agent and who did or
did not take an ACE inhibitor. Hematocrit and hemoglobin were signifi
cantly (P=0.01) lower in the group of patients taking ACE inhibitors (
33+/-6% versus 41+/-5% and 11.5+/-2.0 g/dl versus 14.0+/-1.6 g/dI, res
pectively). Haptoglobin levels were also significantly (P=0.05) lower
in the ACE inhibitor group (116+/-65 mg/dl versus 210+/-114 mg/dl). Er
ythropoietin concentration in the serum and the reticulocyte index wer
e slightly, but not significantly, higher in the ACE inhibitor group b
ut the values were probably too low for their degree of anemia. Compar
ing hematological parameters of the patients in the ACE inhibitor grou
p before and after beginning of the antihypertensive treatment confirm
ed a significant reduction of hematocrit and hemoglobin following ther
apy with an ACE inhibitor. Hematocrit fell from 41+/-7% to 36+/-6% and
hemoglobin from 14.0+/-2.3 g/dl to 11.3+/-1.5 g/dl (P<0.05 for both).
We conclude that the combination of these two drugs should probably b
e avoided.